Recently, the 2021 China Meheco Group Co.Ltd(600056) entrepreneur scientist investor conference (hereinafter referred to as “enlightenment meeting”) opened online and released the “top 100 innovative enterprises in 2021 China Meheco Group Co.Ltd(600056) “. The independent R & D and innovation strength of Shouyao holdings was recognized, and was selected as the “top 100 innovative enterprises in 2021 China Meheco Group Co.Ltd(600056) ” and ranked the second step.
It is reported that the 2021 China Meheco Group Co.Ltd(600056) entrepreneur scientist investor conference is sponsored by China Meheco Group Co.Ltd(600056) Enterprise Management Association, China Meheco Group Co.Ltd(600056) Biotechnology Association and Hangzhou Investment Promotion Bureau. The list of “2021 China Meheco Group Co.Ltd(600056) top 100 innovative enterprises” released by the conference, through model building, data collection and sorting, starting from the current situation of pharmaceutical innovation, taking enterprises as the main body, relying on hard data, and through three dimensions of innovation foundation, innovation process and innovation achievements, based on the number of authorized patents, the total amount of patent introduction Based on the number of clinical trials and the number of innovative drugs approved and listed, the top 100 enterprises representing China Meheco Group Co.Ltd(600056) innovation strength were selected.
Public information shows that the first drug holding (Beijing) Limited by Share Ltd focuses on the development of innovative drugs with independent intellectual property rights for cancer and diabetes. At present, it has applied for more than 100 new drug invention patents worldwide, obtained 18 national class 1 new drug clinical approvals, and won 8 major new drug creation projects in the 12th Five Year Plan and the 13th five year plan. Currently, 2 new drugs have entered the clinical III phase, 2 new drugs have entered the clinical II phase, and 12 new drugs have entered the clinical I stage. The treatment field covers lung cancer, breast cancer, liver cancer, lymphoma, pancreatic cancer and other cancer species.
(China Securities Journal · China Securities Network)
